OUTCOME MEASUREMENT OF MTBI IN CHILDREN AND ADOLESCENTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 尽管轻度创伤性脑损伤(MTBI)是儿童最常见的损伤之一，但对儿童mTBI后的康复过程和长期功能后遗症，包括遗传因素的影响，还缺乏系统的研究。将多态等位基因与神经认知结果联系起来是确定某些基因是否有助于mTBI后恢复的一种策略。然而，等位基因多态研究需要明确定义和验证的结果测量方法和与感兴趣的等位基因频率相适应的样本量。本协议描述了国家儿童医学中心、教育部考阿岛综合体地区、匹兹堡大学医学中心、A.T.斯蒂尔大学和达特茅斯·希区柯克医学中心之间的4阶段、6年多中心合作研究的第一阶段，即试点阶段。第一阶段的目标已经完成，目的是初步开发和适应儿科年龄范围(5-18岁)的mTBI电池的三项主要测试-Impact、Brief和N-Back工作记忆测量。第二阶段的具体目标是开发使用mTBI电池的测试的心理测量学，包括常模、重测可靠性和5-18岁范围内的同时效度。第三阶段的具体目标是临床验证，即建立mTBI电池的敏感性和特异性，以检测mTBI儿童的神经认知和行为变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Although mild traumatic brain injury (mTBI) is among the most common injuries in children, little systemic research has been done regarding the recovery process and long-term functional sequelae of children following mTBI, including the influence of genetic factors. Linking polymorphic alleles to neurocognitive outcome is one strategy to determine if certain genes contribute to recovery after mTBI. However, allelic polymorphism studies require well-defined and validated outcome measures and sample sizes appropriate for the frequency of alleles of interest. This protocol describes the Phase 1, the piloting phase, of a 4-phase, 6-year-multi-center collaborative research study between Children's National Medical Center, the Department of Education-Kaua'i Complex Area, University of Pittsburgh Medical Center, A.T. Still University and Dartmouth Hitchcock Medical Center. The aim of Phase 1, which has already been completed, was the initial development and adaptation of the three principal tests of the mTBI battery for the pediatric age range (5-18 years) - ImPACT, the BRIEF, and the N-back working memory measure. The specific aim of Phase 2 is the psychometric development of the tests with the mTBI battery including norming, test-retest reliability, and concurrent validity across the 5-18 year age range. The specific aim of Phase 3 is clinical validation, i.e., to establish the sensitivity and specificity of the mTBI battery to detect neruocognitive and behavioral changes in children with mTBI.